:: Farmabrasilis

Português

Inglês

Principal | Mapa do Site | Adicione aos Favoritos | Indique o site | Contato

Princípios Atuação

13/07/2015

International Journal of Clinical and Experimental Pathology-Volume 8, Number 5:4277-6011;2015

Alterations in Ubiquitin Ligase Siah-2 and its Corepressor N-CoR after P-MAPA Immunotherapy and Anti-androgen Therapy: New Therapeutic Opportunities for Non-Muscle Invasive Bladder Cancer

01/01/2014

International Immunopharmacology

International Immunopharmacology : Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis

05/05/2013

Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA

Acta tropica: This study investigated the immunotherapeutic potential of the protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immuno-modulator (P-MAPA) on canine visceral leishmaniasis.

18/06/2012

Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Dis./Cancer

Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer: Compounds that can act as agonists for toll-like receptors (TLRs) may be promising candidates for the development of drugs against infectious diseases and cancer. The present study aimed to characterize the immunomodulatory effects of P-MAPA on TLRs in vitro and in vivo, as well as to investigate its potential as adjuvant therapy in infectious diseases and cancer.

10/10/2008

P-MAPA-MONOGRAFIA DE PRODUTO

Preview : Monografia de Produto Farmacêutico contendo informações científicas sobre o Imunomodulador P-MAPA. Suas características fisico-quimicas, propriedades biológicas, estudos pré-clínicos e estudos em seres humanos estão detalhados e discutidos nesta Monografia de Produto, para possibilitar a compreensão e discussão do potencial terapêutico do fármaco

09/10/2008

Antiviral Research-Volume 83, Issue 2, August 2009

Punta Toro virus, has been adapted to induce a Rift Valley fever virus-like disease in C57BL/6 mice. This virus has been used as a model to study the potential role of immunomodulating substances in therapies. Here, we report findings on the use of P-MAPA as an antiviral agent in a mouse model of acute phleboviral (Punta Toro virus) disease

03/10/2008

2nd World Conference - Ehrlich II - Nürnberg - 2008 -Structure and Antimalarial Activity of Immunomodulator P-MAPA

Preview : The P-MAPA activity against malaria ( Plasmodium chabaudi) was evaluated in groups of 7-10 C57BL/6 female mice, 5-8 week-old and pathogen-free.

02/10/2008

Nanonization on biotechnological product: Nanocrystals and its polymorphisms

Preview : The aim of work was to compare two different nanonization processes starting from crystals of P-MAPA with size around 200μm

01/10/2008

Immunopharmacology and Immunotoxicology - Volume 25, Number 3 / 2003

Preview : The present study examined the effects of P-MAPA, an antitumor aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride, isolated from Aspergillus oryzae, on concanavalin A-induced spleen cell proliferation, cytokine production and on NK cell activity in Ehrlich ascites tumor-bearing mice.

01/10/2008

Nitric Oxide 14 - 2006 Macrophage nitric oxide -NO- stimulation by an immunomodulator: P-MAPA

Preview : This study asseded the ability of P-MAPA to modulate NO production by macrophages purified from peritoneal cavity of thioglycolate-treated mice

Lógica Digital

Política de Privacidade | Termo de Uso | copyright @2006 - farmabrasilis - todos os direitos reservados